# Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma

> **NCT00829257** · PHASE4 · COMPLETED · sponsor: **University of Dundee** · enrollment: 15 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** HFA-BDP
- **DRUG:** Fluticasone
- **DRUG:** Seretide

## Key facts

- **NCT ID:** NCT00829257
- **Lead sponsor:** University of Dundee
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00829257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00829257, "Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00829257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*